Cargando…

Oncolytic Viruses for Multiple Myeloma Therapy

Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therape...

Descripción completa

Detalles Bibliográficos
Autores principales: Calton, Christine M., Kelly, Kevin R., Anwer, Faiz, Carew, Jennifer S., Nawrocki, Steffan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025383/
https://www.ncbi.nlm.nih.gov/pubmed/29903988
http://dx.doi.org/10.3390/cancers10060198
_version_ 1783336268235538432
author Calton, Christine M.
Kelly, Kevin R.
Anwer, Faiz
Carew, Jennifer S.
Nawrocki, Steffan T.
author_facet Calton, Christine M.
Kelly, Kevin R.
Anwer, Faiz
Carew, Jennifer S.
Nawrocki, Steffan T.
author_sort Calton, Christine M.
collection PubMed
description Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM therapy with a focus on those agents that have advanced into clinical trials.
format Online
Article
Text
id pubmed-6025383
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60253832018-07-09 Oncolytic Viruses for Multiple Myeloma Therapy Calton, Christine M. Kelly, Kevin R. Anwer, Faiz Carew, Jennifer S. Nawrocki, Steffan T. Cancers (Basel) Review Although recent treatment advances have improved outcomes for patients with multiple myeloma (MM), the disease frequently becomes refractory to current therapies. MM thus remains incurable for most patients and new therapies are urgently needed. Oncolytic viruses are a promising new class of therapeutics that provide tumor-targeted therapy by specifically infecting and replicating within cancerous cells. Oncolytic therapy yields results from both direct killing of malignant cells and induction of an anti-tumor immune response. In this review, we will describe oncolytic viruses that are being tested for MM therapy with a focus on those agents that have advanced into clinical trials. MDPI 2018-06-14 /pmc/articles/PMC6025383/ /pubmed/29903988 http://dx.doi.org/10.3390/cancers10060198 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Calton, Christine M.
Kelly, Kevin R.
Anwer, Faiz
Carew, Jennifer S.
Nawrocki, Steffan T.
Oncolytic Viruses for Multiple Myeloma Therapy
title Oncolytic Viruses for Multiple Myeloma Therapy
title_full Oncolytic Viruses for Multiple Myeloma Therapy
title_fullStr Oncolytic Viruses for Multiple Myeloma Therapy
title_full_unstemmed Oncolytic Viruses for Multiple Myeloma Therapy
title_short Oncolytic Viruses for Multiple Myeloma Therapy
title_sort oncolytic viruses for multiple myeloma therapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6025383/
https://www.ncbi.nlm.nih.gov/pubmed/29903988
http://dx.doi.org/10.3390/cancers10060198
work_keys_str_mv AT caltonchristinem oncolyticvirusesformultiplemyelomatherapy
AT kellykevinr oncolyticvirusesformultiplemyelomatherapy
AT anwerfaiz oncolyticvirusesformultiplemyelomatherapy
AT carewjennifers oncolyticvirusesformultiplemyelomatherapy
AT nawrockisteffant oncolyticvirusesformultiplemyelomatherapy